n-vinyl-2-pyrrolidinone has been researched along with Hyperuricemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Jin, X; Liang, S; Liu, G; Lu, Y; Wang, H; Xu, D; Zhang, X; Zhu, X | 1 |
| Aharodnikau, UE; Jiang, G; Liu, T; Nie, L; Shavandi, A; Solomevich, SO; Sun, Y; Wang, H; Wang, R; Yunusov, KE | 1 |
2 other study(ies) available for n-vinyl-2-pyrrolidinone and Hyperuricemia
| Article | Year |
|---|---|
Nanocapsules of therapeutic proteins with enhanced stability and long blood circulation for hyperuricemia management.
Topics: Animals; Cell Line; Cell Proliferation; Drug Stability; Endocytosis; HeLa Cells; Humans; Hyperuricemia; Immunoglobulin E; Immunoglobulin G; Immunoglobulin M; Male; Mice, Inbred BALB C; Nanocapsules; Pyrrolidinones; Tissue Distribution; Trypsin; Urate Oxidase | 2017 |
Transdermal delivery of allopurinol to acute hyperuricemic mice
Topics: Administration, Oral; Allopurinol; Animals; Hyperuricemia; Mice; Polymers; Povidone; Uric Acid | 2023 |